Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMedOpen access

Ginsenoside Rg1 delays the senescence of adipose-derived stem cells: network pharmacology and experimental validation.

Fang Y., Mou C., Yu X., Zhang J., Zhu W., Zhou C.

Laboratory Study on Chronic Inflammation, published in Hereditas (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Hereditas (2026)
Country
England
Reported sample size
—
Source database
PubMed
PMID
41593745
PMCID
PMC12918114
DOI
10.1186/s41065-026-00646-1

Abstract (original English)

BACKGROUND: Mesenchymal stem cell (MSC) senescence limits their therapeutic potential. Adipose-derived stem cells (ADSCs), though easily accessible, are prone to senescence under oxidative or inflammatory stress. Ginsenoside Rg1, with antioxidant and anti-inflammatory properties, may counteract this process. This study investigates whether Rg1 can alleviate ADSC senescence and its underlying mechanisms. METHODS: To explore the molecular mechanisms by which Ginsenoside Rg1 mitigates ADSC senescence, network pharmacology and molecular docking were applied to identify potential signaling pathways and targets. Cell viability was measured using the Cell Counting Kit-8 (CCK-8) assay to select the optimal modeling concentration. Flow cytometry was used to analyze cell cycle distribution and immune-related marker expression in ADSCs. Reverse transcription quantitative PCR (RT-qPCR) quantified stemness- and senescence-related gene expression. Immunofluorescence (IF) staining assessed senescence-associated protein levels. Western blotting (WB) was performed to examine key proteins in the PI3K/AKT signaling pathway. RESULTS: Network pharmacology identified 22 aging-associated genes targeted by Rg1, with AKT1 emerging as a central hub protein exhibiting high binding affinity. In hydrogen peroxide (H₂O₂)-induced senescence model, Rg1 treatment significantly enhanced cell viability and stemn

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
GinsenosidesCellular SenescenceSignal TransductionMesenchymal Stem CellsNetwork PharmacologyCell SurvivalMolecular Docking SimulationStem CellsAdipose TissueHumans

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research